M8W Stock Overview
A biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
MediWound Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$18.00 |
| 52 Week High | US$20.40 |
| 52 Week Low | US$12.30 |
| Beta | 0.30 |
| 1 Month Change | 27.66% |
| 3 Month Change | 4.65% |
| 1 Year Change | 14.65% |
| 3 Year Change | 54.91% |
| 5 Year Change | 36.05% |
| Change since IPO | -70.54% |
Recent News & Updates
Recent updates
Shareholder Returns
| M8W | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 9.1% | -6.6% | 1.1% |
| 1Y | 14.6% | -25.3% | 16.0% |
Return vs Industry: M8W exceeded the German Pharmaceuticals industry which returned -27.3% over the past year.
Return vs Market: M8W matched the German Market which returned 15% over the past year.
Price Volatility
| M8W volatility | |
|---|---|
| M8W Average Weekly Movement | 8.6% |
| Pharmaceuticals Industry Average Movement | 5.8% |
| Market Average Movement | 6.6% |
| 10% most volatile stocks in DE Market | 12.8% |
| 10% least volatile stocks in DE Market | 3.1% |
Stable Share Price: M8W has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: M8W's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 111 | Ofer Gonen | www.mediwound.com |
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in patients with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx for the treatment of chronic wounds and other hard-to-heal wounds; and MW005, a topically applied biological product candidate to treat non-melanoma skin cancers.
MediWound Ltd. Fundamentals Summary
| M8W fundamental statistics | |
|---|---|
| Market cap | €196.51m |
| Earnings (TTM) | -€26.79m |
| Revenue (TTM) | €17.93m |
Is M8W overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| M8W income statement (TTM) | |
|---|---|
| Revenue | US$20.22m |
| Cost of Revenue | US$17.59m |
| Gross Profit | US$2.63m |
| Other Expenses | US$32.86m |
| Earnings | -US$30.22m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
May 21, 2025
| Earnings per share (EPS) | -2.80 |
| Gross Margin | 13.03% |
| Net Profit Margin | -149.46% |
| Debt/Equity Ratio | 0% |
How did M8W perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/20 09:09 |
| End of Day Share Price | 2025/05/20 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
MediWound Ltd. is covered by 14 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Scott Henry | Alliance Global Partners |
| David Maris | BMO Capital Markets Equity Research |
| Jason Wittes | Brean Capital |